Supreme to Trade on the Canadian Securities Exchange
April 21 2014 - 4:00AM
Marketwired
Supreme to Trade on the Canadian Securities Exchange
CALGARY, ALBERTA--(Marketwired - Apr 21, 2014) - Supreme
Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWF) (CSE:SL)
announces that the Company is moving its listing from the TSX
Venture Exchange to the Canadian Securities Exchange (CSE, formerly
the CNSX) today under the symbol SL. This move will allow the
efficient and seamless transition from a junior resource company to
one whose main focus is now on the emerging medical marijuana
field.
The Company also clarifies its April 15, 2014 cancellation of
its planned financing, which became unnecessary due to exercises to
date of outstanding warrants in excess of $1,000,000. Proceeds from
the warrants exercises exceeded the proposed financing and
management wish to avoid additional dilution.
President and CEO, David Stadnyk stated: "While we have
longstanding relationships with both the TSX Venture and the
Canadian Securities Exchange, we believe this is the right move for
the Company at this time. We now have two producing medical
marijuana facilities under evaluation and expect to report positive
news shortly."
SUPREME PHARMACEUTICALS INC.
David
Stadnyk, President & CEO
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use
of any of the words "anticipate", "continue", "estimate", "expect",
"may", "will", "project", "should", "believe" and similar
expressions are intended to identify forward-looking statements.
Although the Company believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable,
undue reliance should not be placed on the forward-looking
statements because the Company can give no assurance that they will
prove to be correct. Since forward-looking statements address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. These statements speak only as of
the date of this News Release. Actual results could differ
materially from those currently anticipated due to a number of
factors and risks including various risk factors discussed in the
Company's disclosure documents which can be found under the
Company's profile on www.sedar.com. This News Release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Supreme Pharmaceuticals Inc.David StadnykPresident &
CEO(647) 340-6744info@supremepharmaceuticals.comSupreme
Pharmaceuticals Inc.430 - 580 Hornby Street, Vancouver BCV6C
3B6www.supremepharmaceuticals.com